Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Recursion Pharmaceuticals Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 2.7× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| JNK | RXRX | |
|---|---|---|
Market Cap | $5.86B | $2.14B |
Volume | 7,780,002 | 30,789,535 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $6.79 |
52-Week Low | $92.30 | $2.84 |
Typical Hold Time | 61 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.73, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments of $0.53 per share through 2026. Recent institutional activity shows Envestnet Asset Management increased its stake by 23.3% during the latest quarter, indicating institutional confidence despite broader market volatility in high-yield bonds.
The outlook remains cautious amid rising Treasury yields and geopolitical tensions affecting bond markets. Key risks include interest rate sensitivity and economic slowdown concerns. Current technical support sits at $92 with resistance at $93, suggesting limited near-term price movement absent significant market catalysts.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
